Chimeric antigen receptors (CARs) T-cell therapy has become an important approach for cancer treatment.
Develop a novel perfusion-based, beads-free, bioreactor system as a new platform for CAR t-cell manufacturing.
Developed an automatable, scalable, and closed bioreactor system and process for T-cell activation and expansion.
The development of this novel perfusion-based system would facilitate scaling the manufacturing of CAR T cells for different users.
Login to the NIIMBL member portal to access more, including:
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.
Southwest Research Institute
Genentech, Inc.
Merck Sharp & Dohme LLC
University of Pennsylvania
Xcellerate Biotech Inc.
